Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma

Although numerous options are available for patients with recurrent low-grade non-Hodgkin's lymphoma (NHL), responses are rarely durable. We previously conducted a phase I trial of fludarabine and paclitaxel in the treatement of recurrent low-grade lymphoma. The present phase II study was perfo...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2006-09, Vol.47 (9), p.1818-1821
Main Authors: Pro, Barbara, Hagemeister, Fredrick B., McLaughlin, Peter, Romaguera, Jorge, Rodriguez, Maria A., Cabanillas, Fernando, Tiongson, Lili paz, Younes, Anas
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Female
fludarabine
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Low-grade lymphoma
Lymphoma, Follicular - drug therapy
Lymphoma, Non-Hodgkin - drug therapy
Male
Middle Aged
paclitaxel
Paclitaxel - administration & dosage
recurrent lymphoma
Survival Rate
Treatment Outcome
Vidarabine - administration & dosage
Vidarabine - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although numerous options are available for patients with recurrent low-grade non-Hodgkin's lymphoma (NHL), responses are rarely durable. We previously conducted a phase I trial of fludarabine and paclitaxel in the treatement of recurrent low-grade lymphoma. The present phase II study was performed to determine the activity of fludarabine and paclitaxel in patients with recurrent low-grade NHL. Patients with histologically confirmed recurrent low-grade NHL were treated with fludarabine 20 mg m2 day intravenously (i.v.) on days 1 - 5 plus paclitaxel 50 mg m2 given by i.v. continuous infusion over 72 h starting on day 1. Treatment was repeated at 4-week intervals for a maximum of six courses. Twenty-eight evaluable patients were entered into this phase II trial. The median age was 53 years and the median performance status (Zubrod) was 1. Twenty-two (78%) patients had grade 1 or 2 follicular lymphoma, and six patients (21%) had small lymphocytic lymphoma. The median number of prior chemotherapy regimens was 1 (range, 1 - 3). Objective responses occurred in 16 patients (57%); nine patients (32%) achieved a complete remission with a median duration of 32 months (range 4 - 84+ months), and seven patients (25%) had a partial remission. Grade 3 and 4 toxicities included neutropenia (72%), neutropenic fever (34%), infection (13%), mucositis (7%), and neuropathy (3%). The combination of fludarabine and paclitaxel has clinical activity in patients with recurrent low-grade NHL.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428190600684999